7
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Real-World Experience of Efficacy and Safety of Trabectedin in Patients with Soft Tissue Sarcoma: A Bicentric Retrospective Analysis

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction: Soft tissue sarcomas (STSs) are a rare and heterogenous group of tumors, with poor prognostic, judging from their frequency to relapse. Few drugs are available after the conventional first-line regimen. Since 2007, trabectedin got approval after failure of anthracyclines and ifosfamide, for advanced or metastatic STS. This led to a FDA approval in 2015, but real-world evidence is still required, complementary to the pivotal phase II and III trials. Methods: One hundred twenty-six patients with STS, treated by trabectedin between 2002 and 2019, were analyzed in this retrospective study, in two French centers. The effects of trabectedin on survival, response, and toxicity were described. All patients were tested for toxicities, and efficacy was assessed in patients exposed to at least 2 cycles of trabectedin. Results: Three median cycles were administered per patient (1–79). Among the 113 patients analyzed for efficacy, the median progression-free survival was 3.0 months (95% CI: 2.3–4.8), with an overall survival of 12.3 months (95% CI: 10.2–16.9). The rate of disease control was 46% at the end of treatment. Myxoid liposarcoma ( n = 11) was the histology subtype that benefited most from this chemotherapy with median progression-free survival and overall survival of 13.3 months (95% CI: 2.3–18.7) and 27.8 months (95% CI: 3.2–64.7), respectively. Adverse events were manageable. Discussion and Conclusion: Efficacy of trabectedin is confirmed in terms of clinical benefit and low toxicity, especially for myxoid liposarcoma. Combinatory regimens are under clinical trials to optimize the place of this chemotherapy.

          Related collections

          Author and article information

          Journal
          OCL
          Oncology
          10.1159/issn.0030-2414
          Oncology
          Oncology
          S. Karger AG
          0030-2414
          1423-0232
          2022
          December 2022
          25 October 2022
          : 100
          : 12
          : 633-644
          Affiliations
          [_a] aDepartment of Oncology, University Hospital of Besançon, Besançon, France
          [_b] bINSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire Et Génique, Besançon, France
          [_c] cDepartment of Pharmacy, University Hospital of Besançon, Besançon, France
          [_d] dDepartment of Oncology, Centre Georges-François Leclerc, Dijon, France
          [_e] eDepartment of Radiology, University Hospital of Besançon, Besançon, France
          [_f] fDepartment of Pathology, Centre Georges-François Leclerc, Dijon, France
          [_g] gDepartment of Pediatric Oncology, University Hospital of Dijon, Dijon, France
          [_h] hDepartment of Oncology, Pôle Régional de Cancérologie, University Hospital of Poitiers, Poitiers, France
          [_i] iINSERM, Centre d’Investigation Clinique 1402, Poitiers, France
          [_j] jPRODICET UR24144, Poitiers, France
          Author information
          https://orcid.org/0000-0002-4938-9470
          https://orcid.org/0000-0002-0351-6040
          https://orcid.org/0000-0003-1724-5939
          Article
          527602 Oncology 2022;100:633–644
          10.1159/000527602
          36283345
          5ff43ff9-af51-4fff-ac73-3f26d5c03777
          © 2022 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.

          History
          : 25 April 2022
          : 23 September 2022
          Page count
          Figures: 5, Tables: 4, Pages: 12
          Funding
          There were no sources of funding.
          Categories
          Clinical Study

          Medicine
          Efficacy,Toxicity,Soft tissue sarcoma,Trabectedin
          Medicine
          Efficacy, Toxicity, Soft tissue sarcoma, Trabectedin

          Comments

          Comment on this article